文献速递淋巴瘤

如何管理接受持续肿瘤导向治疗的慢性淋巴细胞白血病患者的围手术期

How we approach the perioperative management of patients with chronic lymphocytic leukaemia receiving continuous cancer-directed therapies.
PubMed 文献 · Br J Haematol · 2023-01-22

本文针对接受持续肿瘤导向治疗的慢性淋巴细胞白血病(CLL)患者,总结了相关药物的副作用与药物相互作用,分析了潜在手术风险,并就围手术期暂停特定CLL药物给出推荐。

要点

  • 新型持续治疗显著改善CLL预后,患者预期寿命延长,可接受各类有创操作及大手术。
  • 需关注持续CLL治疗的副作用及药物相互作用,评估围手术期手术风险。
  • 本文就围手术期暂停特定CLL药物提供推荐。

核心结论

  • 新型持续治疗显著改善CLL结局,部分患者可预期数年治疗反应和疾病控制,克服了既往阻碍介入操作者的短预期寿命问题。

研究设计与样本

  • 本文为综述,总结持续CLL治疗的相关副作用和药物相互作用,分析潜在手术风险,并就围手术期暂停特定CLL药物提供推荐。

主要发现

  • 历史上因预期寿命有限,晚期CLL等血液恶性肿瘤患者的有创操作和手术被推迟。
  • 新型且常为持续性的治疗显著改善了CLL结局,部分患者可预期数年治疗反应和疾病控制。
  • 此类患者现在常接受包括大手术在内的各种有创操作。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Historically, invasive procedures and surgeries were deferred in patients with haematological malignancies including advanced stage chronic lymphocytic leukaemia (CLL) because of limited life expectancy. However, novel, and often continuous, treatments have markedly improved outcomes in CLL. Some patients may expect years of treatment response and disease control, overcoming the short life expectancy that deters interventionalists. Such patients now often undergo various invasive procedures including major surgery. To inform peri-operative management, we summarize the relevant side effects and drug interactions of continuous CLL therapies, highlight potential surgical risks, and provide recommendations on withholding specific CLL drugs around invasive procedures.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ma H, Wang S, O'Brien S, et al. How we approach the perioperative management of patients with chronic lymphocytic leukaemia receiving continuous cancer-directed therapies. Br J Haematol. 2023. PMID: 36682358. doi:10.1111/bjh.18661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。